#GI25 BREAKWATER Scott Kopetz changing the paradigm yet again! The true master of BRAF and colorectal targeted therapy. BRAF+ first line mCRC; n=236 on experimental arm Enco (BRAF) + Cetux (EGFR)+ FOLFOX ORR 60% vs 40%! OS not yet reached!!! Durable responses and twice as

Always great to learn new data in SF and connect with mentors + friends ASCO GI. Thanks to Conquer Cancer, the ASCO Foundation for the Merit Award that allowed it to happen. Check out our work describing how ctDNA can be used to track response to IO in pts with dMMR/MSI-H CRC 👇 #GI25

Should I Get Tested for H. Pylori? news.umiamihealth.org/en/should-i-ge… #Hpylori #STCSM #ESOCSM Sylvester Comprehensive Cancer Center

In this review, Cindy M. Pabon, MD et al summarize recent data on the optimal preoperative strategy for esophageal or gastro-esophageal junction (GEJ) cancers. doi.org/10.1093/oncolo…

Did you know that colorectal cancer is one of the most preventable cancers, yet it's still a leading cause of cancer deaths? Regular screenings are key, especially if you're 45 or older. Our expert Nick Hornstein, MD, PhD, (Nicholas Hornstein) a medical oncologist specializing in

A shameless, non-self-promoting post for my absolute rockstar partner, Jash Datta, MD. He made a compelling argument in favor of the intricate tumor microenvironment being the key 🔑regulator in PDAC treatment response over the singular KRAS initiating mutation. #SSO2025

Is there anything in your diet that can increase the chances of developing #stomach #cancer? Tune in as Dr. Cindy Pabon (Cindy M. Pabon, MD), oncologist and assistant lead of #GI cancer clinical #research, breaks it down and answers your question. Learn more: loom.ly/RRHKxzY

This study was born from personal experiences and nostalgia We hoped that these findings would provoke conversations and demand change I never anticipated the country to go backwards rather than forward Narjust Florez, MD, FASCO #FlorezLab Ana I. Velázquez Mañana, MD, MSc, FASCO Claudia Villa Celi Arun Umesh Mahtani

Here is the thing friends… She went for it! I am running for the IASLC Board of Directors because I believe in the organization & all it can do for our patients and community And we together can make a DIFFERENCE Undesignated Group # 4 - Vote 🗳️ #LCSM

Stomach cancer is tough to detect early and often diagnosed late. Sylvester experts are tackling it through prevention, biomarker-driven treatment and clinical trials testing new #immunotherapies. Learn more: loom.ly/dNJHPQE. Cindy M. Pabon, MD Marijo Bilusic, MD, PhD

Have you signed up for #MiamiNights yet? Sylvester Comprehensive Cancer Center @asco #asco25 We are hiring - Looking for chiefs for breast and head and neck and oncologists in pretty much all areas DM me @glopesmd

Join tomorrow morning at 9 AM to learn about #pancreaticcancer subtyping, biomarkers and vaccine research Peter Hosein, MD Sylvester Comprehensive Cancer Center

Great presentation by Peter Hosein, MD from Sylvester Comprehensive Cancer Center on pancreas subtypes. Nice to see progress in pancreatic cancer with use of vaccines.

Our very own Dr. Peter Hosein (Peter Hosein, MD) presented "Is Pancreas Subtyping Ready for Prime Time?" at #ASCO25 in a panel discussion focused on #PancreaticCancer research findings. Learn more about our presence: Sylvester.org/ASCO2025.

Who says working on your birthday can’t be fun?! Loved spending it with my Sylvester Comprehensive Cancer Center team 🤗

Pleased to report FGFR2b expression in gastric cancer and relationship with other biomarkers ESMO Open ESMO - Eur. Oncology. The results of bemarituzumab phase 3 studies are awaited.OncoAlert OncoDaily sciencedirect.com/science/articl…

📢Gastroesophageal cancers oral abstracts in #ESMO25 ESMO - Eur. Oncology 👇 #cancer #oncology #GI #gastric #esophageal OncoAlert Dr Joseph McCollom DO Eduardo Terán Sergio Cifuentes

We have an unexpected opening in our gastrointestinal pathology fellowship for 2026-2027 at the University of Miami. If you are interested, please contact [email protected] - include your CV!

Pleased to share our experience of zolbetuximab induced gastritis ESMO - Eur. Oncology ESMO Open More anorexia & albumin decline in diffuse gastritis, yet reversible without discontinuation. Careful differentiation with gastritis vs disease progression needed. sciencedirect.com/science/articl…

Are you an oncology attending—anywhere in the world? 🌍 Join The Hidden Struggle Study exploring anxiety, depression & burnout among oncology physicians. 🧠 Fill a short survey & make your voice count. DM or email [email protected] for the form. #PhysicianWellbeing